EUCTR2014-004796-23-CZ进行中（未招募）1 期
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 123
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Female aged > 18 years.
- •2.Patients with pathologically documented metastatic triple negative breast cancer (TNBC), eligible for treatment with paclitaxel. Paraffin-embedded tissue must be available from metastatic sites, if reasonably accessible, or from the primary tumor, to confirm the diagnosis of TNBC and for correlative studies (only on metastatic tissue). Fifteen slides can be obtained if the full block is not available to be sent or released.
- •TNBC will be defined as breast cancer with <1% ER+ and <1% PgR+ cells, and HER2 immunohistochemistry score of 0 or 1+ and/or in situ hybridization (ISH) with HER2 gene copy number <4 or a ratio of less than 2 between HER2 gene copy number and centromere of chromosome 17. Patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2.
- •3.Patients must be newly diagnosed metastatic or have relapsed following a prior (neo)adjuvant chemotherapy regimen. If a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. For non-taxane (neo)adjuvant regimen, PD must have occurred > 6 months from the end of previous (neo)adjuvant treatment
- •4.Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1.
- •5.Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0 1.
- •6.Life expectancy of at least three months.
- •7.Patients must be able to swallow and retain oral medication (intact tablet).
- •8.Able to undergo all screening assessments outlined in the protocol.
- •9.Adequate organ function (defined by the following parameters):
- •a)Serum creatinine < 140 µmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min.
- •b)Serum hemoglobin = 9 g/dL; absolute neutrophil count = 1.5 x 109/L; platelets = 100 x 109/L.
- •c)Serum bilirubin = 1.5 x upper normal limit (UNL) except patients with Gilbert’s syndrome
- •d)Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) = 2.5 x UNL but = 5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP) = UNL but I) = 2.5 x ULN in case of liver metastases and ii) = 5x ULN in case of bone metastases; albumin > 2.5g/dl.
- •10.No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease.
- •11.No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus I? and II positive status.
- •12.Dated and signed IEC/IRB-approved informed consent.
- •13. No history or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Medical Monitor, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 105
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 51
排除标准
- •2.Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease.
- •3.Less than four weeks since last radiotherapy (excluding palliative radiotherapy).
- •4.Pregnancy or lactation or unwillingness to use adequate method of birth control.
- •5.Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.
- •6.Active or uncontrolled infection.
- •7.Malabsorption syndrome, disease significantly affecting gastrointestinal function.
- •8.G>1 pre-existing peripheral neuropathy
- •9.Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer
- •10.Hypersensitivity to:
- •a)paclitaxel
- •b)ibuprofen or to more than one non-steroidal anti-inflammatory drug.
- •c)more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib; hypersensitivity to sulphanilamide antibiotics alone (e.g.sulfamethoxazole) does not qualify for exclusion.
研究者
相似试验
进行中（未招募）
1 期
A study to test whether pazopanib can prevent or delay kidney tumor coming back after the tumor has been removedRenal Cell CarcinomaEUCTR2010-020965-26-SKovartis Pharma Services AG1,500
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib - BAY73-4506 Phase III GIST 3rd/4th lineEUCTR2009-017957-37-FRBayer HealthCare AG170
进行中（未招募）
1 期
Study of Reparixin combined with paclitacel compared to paclitaxel alone in patients with metastatic Triple-negative breast cancerEUCTR2014-004796-23-PLDompé Farmaceutici s.p.a.123
进行中（未招募）
1 期
16-week efficacy and 3-year safety, tolerability and efficacy of secukinumab in active ankylosing spondylitis patientsEUCTR2013-001090-24-BEovartis Pharma Services AG222
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura (ITP). - RAISEEUCTR2006-000470-78-FRGlaxoSmithKline Research and Development Limited